Aptus san diego
![aptus san diego aptus san diego](https://aptuscr.com/wp-content/uploads/2015/04/061515_Aptus_-26.jpg)
![aptus san diego aptus san diego](https://aptuscr.com/wp-content/uploads/2015/07/jaclyn-swe-new-sm.jpg)
Gorgas, President and CEO of Artelo Biosciences commented “Artelo are excited to be starting the CAReS trial investigating ART27.13 in patients who currently have no licensed options to alleviate the devastating condition of cancer-associated anorexia. We are excited to be working with Artelo in assessing whether ART27.13 can make a difference to patients who are suffering from this distressing condition and improve their quality of life. Steve McConchie, CEO at Aptus Clinical said ‘The CAReS study is an important investigation in cancer anorexia, and we are delighted that the partnership we have developed with Artelo has achieved the important milestone of first patient recruited and dosed.
![aptus san diego aptus san diego](https://aptuscr.com/wp-content/uploads/2015/04/061515_Aptus_-25.jpg)
#Aptus san diego full
Aptus Clinical, as the full service CRO provider for the Phase 1b/2a Cancer Appetite Recovery Study (CAReS), has assisted Artelo Biosciences in the planning and running of this important study which investigates the potential for ART27.13 (a peripherally synthetic cannabinoid agonist), to alleviate anorexia associated with cancer, a condition with significant unmet need and no licensed treatments.